Hexagon Bio

Executive Summary

Hexagon Bio is a private biotechnology company headquartered in Menlo Park, California, that is pioneering next-generation antibody-drug conjugates (ADCs) for cancer therapy. Founded in 2016, the company leverages a unique platform combining computational biology and natural product discovery to identify novel cytotoxic payloads. These payloads are designed to overcome resistance mechanisms that limit the efficacy of current ADC therapies, potentially expanding the therapeutic index and addressing a broader range of solid tumors. By focusing on novel mechanisms of action, Hexagon aims to differentiate its ADCs from the crowded field of competitors targeting established payloads like auristatins and maytansinoids. The company's approach is particularly relevant as the ADC market matures and resistance to existing therapies becomes a growing clinical challenge. While Hexagon Bio has not publicly disclosed its total funding or valuation, its presence in the biopharma hub of Silicon Valley suggests strong investor interest in its platform-based strategy. The company remains in the preclinical or early clinical stage, with no approved products or disclosed pipeline details, yet its technology holds promise for addressing key unmet needs in oncology.

Upcoming Catalysts (preview)

• H2 2026IND filing for lead ADC program40% success
• H1 2026Disclosure of preclinical data for novel payload platform65% success
• 2026Potential partnership or licensing deal with a larger pharma30% success